# The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct06861088/  
OnCo record `nct06861088` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Kinisoquin™ in pancreatic ductal adenocarcinoma, run by Quercis Pharma AG, now recruiting.

## Summary

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer is a phase 3 interventional study registered as NCT06861088 by Quercis Pharma AG, with 480 participants planned, started 2025-12-19 and due to reach its primary completion in 2027-10-31. Interventions recorded: Kinisoquin™ and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06861088
- Phase: 3
- Setting: A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer (CATIQ P3)
- Sponsor: Quercis Pharma AG
- Enrolled: 480

## Sources

- ClinicalTrials.gov NCT06861088: https://clinicaltrials.gov/study/NCT06861088

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct06861088.json